Compare INUV & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INUV | CALC |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0M | 19.1M |
| IPO Year | 1996 | 2020 |
| Metric | INUV | CALC |
|---|---|---|
| Price | $0.72 | $0.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $11.00 | $10.00 |
| AVG Volume (30 Days) | 280.0K | ★ 294.7K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $86,209,305.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.89 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.88 | N/A |
| 52 Week Low | $0.71 | $0.46 |
| 52 Week High | $4.42 | $7.20 |
| Indicator | INUV | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 30.92 | 38.48 |
| Support Level | N/A | $0.51 |
| Resistance Level | $1.16 | $0.77 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 5.76 | 4.18 |
Inuvo Inc is an advertising technology and services company that has developed and commercialized large language generative artificial intelligence (AI) for modeling media audiences. Its products and services include ValidClick and IntentKey. The company's platforms identify and message online audiences for any product or service across devices, channels, and formats, including video, mobile, connected TV, display, social, and native. It has clients from various industries that include retail, automotive, insurance, health care, technology, telecommunications and finance. Inuvo's revenue is derived from the placement of digital advertising throughout devices, websites, applications and browsers across social, search and programmatic advertising channels.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.